Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo, Ezetimibe placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 16
States / cities: Los Angeles, California • Northridge, California • Ocala, Florida + 13 more

Conditions: Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions: Metformin, Placebo; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 1, Hyperlipidemias
Interventions: Colesevelam HCl, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy; Drug
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 4
States / cities: Columbus, Ohio • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Hyperlipidemia, Hypercholesterolemia
Interventions: Niacin, Colestipol, Ezetimibe; Drug
Lead sponsor: Tuscaloosa Research & Education Advancement Corporation; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: HIV Infections, Hypertriglyceridemia
Interventions: Fenofibrate, Fish Oil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Cincinnati, Ohio + 2 more

Conditions: Severe Hypertriglyceridemia
Interventions: placebo, omefas; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: National City, California • Sacramento, California • Manchester, Connecticut + 25 more

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl tablets, and simvastatin tablets, simvastatin tablets and colesevelam HCl placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 14
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 11 more

Conditions: Elevated Lipoprotein(a), Cardiovascular Disease
Interventions: ISIS 681257, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more

Conditions: Cardiovascular Disease, Hypertension, Diabetes, Hyperlipidemia
Interventions: Pharmacist CVD; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lipodystrophy
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypercholesterolemia, Familial Hypercholesterolemia
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 49
States / cities: Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 45 more

Conditions: Hyperlipidemias, Hyperglycemia
Interventions: Golden Black Seed; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 40 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: High Triglycerides
Interventions: NST-1024, Placebo; Drug · Other
Lead sponsor: NorthSea Therapeutics B.V.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more

Conditions: Atherosclerosis, Hypercholesterolemia
Interventions: fasudil; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis, Cardiovascular Diseases
Interventions: Soy bread; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertriglyceridemia
Interventions: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 32
States / cities: Spring Valley, California • Washington D.C., District of Columbia • Coral Gables, Florida + 27 more

Conditions: Obesity, Hypercholesterolemia, Cardiovascular Disease
Interventions: Plant-Based Diet, American Heart Association Diet, Mediterranean Diet; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 9 Years to 18 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypercholesterolemia
Interventions: AVE5530, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 826 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hypercholesterolemia
Interventions: Ezetimibe 10 mg, Ezetimibe 5 mg; Drug
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hypercholesterolemia and Hyperlipidemia
Interventions: Ketogenic Diet, Control Diet; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 39 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypercholesterolemia, Familial, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 14
States / cities: San Diego, California • Washington D.C., District of Columbia • Lutz, Florida + 11 more

Conditions: Hypercholesterolemia
Interventions: PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316), PF-04950615; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 74
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 59 more

Conditions: Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
Interventions: Rosuvastatin (Crestor), Ezetimibe, Simvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Brentwood, Tennessee

Search by objective public record fields.

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

The Effects of Metformin on Blood Vessel Structure and Function

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501

A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction

The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)

Epanova® for Lowering Very High Triglycerides

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Cardiovascular Intervention Improvement Telemedicine Study

Leptin to Treat Lipodystrophy

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Golden Black Seed: Support of Metabolic Health and General Wellness.

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

The Effect of Fasudil on Vascular Function in Humans

Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

Plant-Based, American Heart Assoc. or Mediterranean Diets In 9-18 yo With BMI >95%, Cholesterol >169 and Their Parents

Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia

Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe